Aztiq and Innobic Consortium Acquires Alvogen Emerging Markets Holdings for $500M

Aztiq Pharma Partners Invests $100M to Buy 17% Stake in Alvogen US

June 30, 2021

Pharmaceuticals

Aztiq Pharma Partners completed a $100 million financing to acquire a newly issued 17% equity stake in Alvogen US at a pre-money valuation of $350 million, with Morgan Stanley leading the financing. The funding will support increased R&D investment and expansion of branded sales channels in the U.S., and following the transaction Aztiq holds a combined direct and indirect stake of approximately 40% in Alvogen US.

AstraZeneca (Alexion) Acquires Amolyt Pharma for Up to $1.05 Billion

March 14, 2024

Biotechnology

Amolyt Pharma, a clinical-stage biotech focused on rare endocrine diseases, entered into a definitive agreement to be acquired by AstraZeneca’s Rare Disease business (Alexion) for $800 million upfront plus up to $250 million in regulatory milestone contingent payments. The total deal value is up to $1.05 billion and is expected to close by the end of Q3 2024, subject to customary closing conditions and regulatory clearances.

EQT X to Acquire Adalvo (B2B Generic Drug Dossiers)

July 18, 2025

Healthcare Services

EQT X (EQT) has agreed to acquire a majority stake in Adalvo, an asset-light B2B dossier developer that produces market-approval-ready generic drug dossiers for pharmaceutical companies. Existing shareholders, including Aztiq (holding company of Chairman Róbert Wessman), will reinvest part of their holdings and retain minority ownership. The deal is subject to customary approvals and is expected to close in H2 2025.

Alkermes plc Acquires Avadel Pharmaceuticals plc

February 12, 2026

Pharmaceuticals

Alkermes plc completed its all-cash acquisition of Avadel Pharmaceuticals plc under an Irish High Court‑sanctioned scheme of arrangement, adding Avadel's FDA‑approved product LUMRYZ to Alkermes' commercial portfolio. The deal accelerates Alkermes' entry into the sleep medicine market, is expected to be accretive in 2026, and includes Avadel's clinical candidate valiloxybate.

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.

Altasciences Acquires Alliance Contract Pharma

February 27, 2020

Pharmaceuticals

Altasciences, a mid-size contract research organization based in Laval, Quebec, has acquired Alliance Contract Pharma to add small-molecule contract manufacturing and analytical services, including commercial manufacturing, GMP warehouse storage, and clinical supply distribution. The acquisition expands Altasciences' integrated early‑phase drug development offering by adding manufacturing and analytical capabilities to its preclinical, clinical, and bioanalytical services.